277 related articles for article (PubMed ID: 25934575)
1. Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms.
Calinski DM; Zhang H; Ludeman S; Dolan ME; Hollenberg PF
Drug Metab Dispos; 2015 Jul; 43(7):1084-90. PubMed ID: 25934575
[TBL] [Abstract][Full Text] [Related]
2. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide.
Huang Z; Roy P; Waxman DJ
Biochem Pharmacol; 2000 Apr; 59(8):961-72. PubMed ID: 10692561
[TBL] [Abstract][Full Text] [Related]
3. Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes.
Granvil CP; Madan A; Sharkawi M; Parkinson A; Wainer IW
Drug Metab Dispos; 1999 Apr; 27(4):533-41. PubMed ID: 10101149
[TBL] [Abstract][Full Text] [Related]
4. Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation.
McCune JS; Risler LJ; Phillips BR; Thummel KE; Blough D; Shen DD
Drug Metab Dispos; 2005 Jul; 33(7):1074-81. PubMed ID: 15821045
[TBL] [Abstract][Full Text] [Related]
5. Role of cytochrome P450 in oxazaphosphorine metabolism. Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450.
Yu L; Waxman DJ
Drug Metab Dispos; 1996 Nov; 24(11):1254-62. PubMed ID: 8937861
[TBL] [Abstract][Full Text] [Related]
6. CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes.
Schmidt R; Baumann F; Knüpfer H; Brauckhoff M; Horn LC; Schönfelder M; Köhler U; Preiss R
Br J Cancer; 2004 Feb; 90(4):911-6. PubMed ID: 14970873
[TBL] [Abstract][Full Text] [Related]
7. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation.
Chang TK; Yu L; Goldstein JA; Waxman DJ
Pharmacogenetics; 1997 Jun; 7(3):211-21. PubMed ID: 9241661
[TBL] [Abstract][Full Text] [Related]
8. Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants.
Vredenburg G; den Braver-Sewradj S; van Vugt-Lussenburg BM; Vermeulen NP; Commandeur JN; Vos JC
Toxicol Lett; 2015 Jan; 232(1):182-92. PubMed ID: 25448283
[TBL] [Abstract][Full Text] [Related]
9. Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer.
Roy P; Tretyakov O; Wright J; Waxman DJ
Drug Metab Dispos; 1999 Nov; 27(11):1309-18. PubMed ID: 10534317
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide.
May-Manke A; Kroemer H; Hempel G; Bohnenstengel F; Hohenlöchter B; Blaschke G; Boos J
Cancer Chemother Pharmacol; 1999; 44(4):327-34. PubMed ID: 10447581
[TBL] [Abstract][Full Text] [Related]
11. Gender difference in ifosfamide metabolism by human liver microsomes.
Schmidt R; Baumann F; Hanschmann H; Geissler F; Preiss R
Eur J Drug Metab Pharmacokinet; 2001; 26(3):193-200. PubMed ID: 11695720
[TBL] [Abstract][Full Text] [Related]
12. Stereoselectivity in metabolism of ifosfamide by CYP3A4 and CYP2B6.
Lu H; Wang JJ; Chan KK; Philip PA
Xenobiotica; 2006 May; 36(5):367-85. PubMed ID: 16854777
[TBL] [Abstract][Full Text] [Related]
13. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide.
Walker D; Flinois JP; Monkman SC; Beloc C; Boddy AV; Cholerton S; Daly AK; Lind MJ; Pearson AD; Beaune PH
Biochem Pharmacol; 1994 Mar; 47(7):1157-63. PubMed ID: 8161344
[TBL] [Abstract][Full Text] [Related]
14. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines.
Chang TK; Yu L; Maurel P; Waxman DJ
Cancer Res; 1997 May; 57(10):1946-54. PubMed ID: 9157990
[TBL] [Abstract][Full Text] [Related]
15. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics.
Chen CS; Lin JT; Goss KA; He YA; Halpert JR; Waxman DJ
Mol Pharmacol; 2004 May; 65(5):1278-85. PubMed ID: 15102956
[TBL] [Abstract][Full Text] [Related]
16. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles.
Roy P; Yu LJ; Crespi CL; Waxman DJ
Drug Metab Dispos; 1999 Jun; 27(6):655-66. PubMed ID: 10348794
[TBL] [Abstract][Full Text] [Related]
17. Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide.
Preiss R; Schmidt R; Baumann F; Hanschmann H; Hauss J; Geissler F; Pahlig H; Ratzewiss B
J Cancer Res Clin Oncol; 2002 Jul; 128(7):385-92. PubMed ID: 12136253
[TBL] [Abstract][Full Text] [Related]
18. Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase.
Velazquez MNR; Parween S; Udhane SS; Pandey AV
Biochem Biophys Res Commun; 2019 Jul; 515(1):133-138. PubMed ID: 31128914
[TBL] [Abstract][Full Text] [Related]
19. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes.
Chang TK; Weber GF; Crespi CL; Waxman DJ
Cancer Res; 1993 Dec; 53(23):5629-37. PubMed ID: 8242617
[TBL] [Abstract][Full Text] [Related]
20. Effects of anthocyanidins and anthocyanins on the expression and catalytic activities of CYP2A6, CYP2B6, CYP2C9, and CYP3A4 in primary human hepatocytes and human liver microsomes.
Srovnalova A; Svecarova M; Zapletalova MK; Anzenbacher P; Bachleda P; Anzenbacherova E; Dvorak Z
J Agric Food Chem; 2014 Jan; 62(3):789-97. PubMed ID: 24387788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
